OncoMatch/Clinical Trials/NCT07085091
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Is NCT07085091 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including ALX2004 and ALX2004 for nsclc (advanced non-small cell lung cancer).
Treatment: ALX2004 · ALX2004 · ALX2004 — A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Esophageal Carcinoma
Prior therapy
Must have received: anticancer therapy — advanced/metastatic
relapsed or progressed following prior anticancer therapy in the advanced/metastatic setting and for whom no approved or standard therapy is available
Cannot have received: antibody-drug conjugate
Exception: that have an active TOP1 inhibitor-based component
Prior treatment with any ADCs that have an active TOP1 inhibitor-based component
Lab requirements
Blood counts
Adequate Bone Marrow Function
Kidney function
Adequate Renal Function
Liver function
Adequate Liver Function
Adequate Bone Marrow Function; Adequate Renal & Liver Function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- ALX Center 7 · Tampa, Florida
- ALX Center 3 · Grand Rapids, Michigan
- ALX Center 6 · Portland, Oregon
- ALX Center 5 · Houston, Texas
- ALX Center 4 · West Valley City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify